Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of TTNP stock opened at $6.97 on Tuesday. The stock has a market capitalization of $6.34 million, a PE ratio of -0.85 and a beta of 1.33. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60. The business has a 50-day moving average of $7.36 and a 200 day moving average of $7.16.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.